February 20, 2026
Poland’s regulated market for prescription-based flower and extracts grew quickly—and then hit a hard compliance “reset” in late 2024 and throughout 2025. Two forces are converging:
For operators, the headline is simple: Poland is not “closing” the market, but it is raising the cost of being sloppy. Importers, brand owners, clinics, pharmacies, and online retailers should assume more scrutiny, more documentation requests, and faster delisting actions.
This article is informational only, not legal advice.
Poland’s regulators are responding to a broader healthcare integrity problem: remote prescribing at scale, sometimes with minimal clinical assessment, and an e‑prescription system that can be exploited if governance is weak. At the same time, Polish authorities operate within EU food law, where CBD extracts for ingestion generally fall under Novel Food rules unless a valid authorization applies.
In practice, 2025 is a year where:
Industry coverage and legal commentary indicate that Poland moved to limit the ability of specialist clinics to issue prescriptions via teleconsultation without an in‑person examination—especially for controlled medicines. For example, CMS reported that the Ministry of Health discussed changes where only primary care physicians would be able to issue certain prescriptions during an online consultation, reflecting a tightening stance for controlled products.
Multiple industry sources cite a notable drop from the peak in October 2024 following the restriction of online prescribing.
While these are not official government statistical releases, they are consistent with the enforcement narrative: remote prescribing is being re‑anchored to clinical accountability and traceable medical justification.
A compliant model is not simply “video call + e‑prescription.” Clinics should treat remote care as a documentation-heavy medical service with clear triggers for in‑person review.
Key expectations to operationalize:
If your organization operates clinics (or partners with them), your compliance posture should be able to answer: “Why was this prescription appropriate for this patient, on this date, via this modality?”
A conservative pathway many operators are adopting:
Why it matters: if audited, the first in‑person exam provides a strong anchor for medical necessity.
If telemedicine initiation is still used in limited cases, the compliance burden goes up:
Brands should avoid building demand forecasts around “instant online prescriptions.” That channel is now structurally less reliable.
Poland’s model routes products through pharmacies, and controlled‑substance expectations cascade down to dispensing and recordkeeping.
Poland has continued modernizing its e‑prescription environment, and reporting indicates that prescriptions for narcotic/psychotropic products are issued electronically under tightened rules.
Even if you don’t operate the pharmacy, your supply chain will be judged by how “clean” it is:
Poland’s import and distribution of controlled substances sits within a licensing framework overseen by the Chief Pharmaceutical Inspectorate (GIF / Chief Pharmaceutical Inspectorate).
GIF’s official information for entrepreneurs and the controlled substances area highlights its role in issuing approvals for import or intra‑Community acquisition of narcotic drugs and psychotropic substances.
What importers should have organized (and retrievable fast):
Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) is the authority maintaining the Register of Medicinal Products admitted to trade.
The strategic takeaway: do not blur categories. A product should be clearly positioned and documented as a medicinal product, a medical device, a cosmetic, or a food supplement/food—and your labels, claims, and online listings must match that classification.
Under Regulation (EU) 2015/2283, a Novel Food requires pre‑market authorization if it was not consumed to a significant degree in the EU before 15 May 1997. EU institutions have long treated extracts containing cannabinoids (including CBD) as Novel Food absent a demonstrated history of consumption.
This is why “CBD oil as a food supplement” remains a high‑risk category in most EU countries, including Poland.
The RASFF Window (EU Rapid Alert System for Food and Feed) provides concrete examples of enforcement focus. In 2025, notifications explicitly reference unauthorized Novel Food CBD offered for sale online from Poland, with measures including sales bans.
For brands, this matters even if you are not based in Poland: cross‑border e‑commerce makes your Polish listing visible to other Member States, and enforcement can be triggered externally.
One reason the Novel Food pathway remains difficult is that EFSA has repeatedly highlighted data gaps around CBD safety. EFSA’s updated communication sets a provisional safe intake level while underscoring ongoing uncertainties.
Even if your dossier strategy is strong, your commercial plan must account for:
A Novel Food application is not a “formality.” It is a technical file intended to support EU‑wide authorization.
Common dossier elements to plan for:
Where brands commonly fail in Poland (and get delisted):
Poland’s Chief Sanitary Inspectorate (GIS) supervises food supplements. Market entry often involves notification rather than a formal pre‑approval, but that does not protect products that violate Novel Food or claims rules.
In other words: you can notify a supplement and still be investigated, challenged, or removed.
A practical overview of the notification concept (non‑official but consistent with practice) is widely described by Polish regulatory service providers, emphasizing that notification can trigger verification and withdrawals.
The commercial takeaway: treat GIS notification as a starting point for scrutiny, not a compliance shield.
In 2025, many brands underestimate the most immediate enforcement consequence: retailer delisting and payment/fulfillment disruption.
Triggers for delisting in Poland commonly include:
Once delisted, reinstatement typically requires more than “updated copy.” Expect requests for:
In Poland, the fastest way to reduce enforcement exposure is to stop straddling categories.
Actions:
Your website, product page, customer service scripts, influencer briefs, and FAQs should be reviewed to remove:
Treat claims compliance as part of cannabis compliance in the broad sense: enforcement often begins with marketing.
For each product, maintain a shareable folder containing:
This reduces downtime when platforms, distributors, or inspectors ask questions.
The telemedicine shift and delisting events can create sudden drops in access.
Brands that handle this well:
Plan for at least three operational scenarios:
If you operate in Poland—or sell into Poland via EU e‑commerce—2025’s reset is a reminder that compliance is your distribution strategy. Use https://cannabisregulations.ai/ to track regulatory updates, map compliant prescription and dispensing workflows, and build documentation checklists that hold up under scrutiny.
Informational only; consult qualified counsel for legal advice.
Poland’s regulated market for prescription-based flower and extracts grew quickly—and then hit a hard compliance “reset” in late 2024 and throughout 2025. Two forces are converging:
For operators, the headline is simple: Poland is not “closing” the market, but it is raising the cost of being sloppy. Importers, brand owners, clinics, pharmacies, and online retailers should assume more scrutiny, more documentation requests, and faster delisting actions.
This article is informational only, not legal advice.
Poland’s regulators are responding to a broader healthcare integrity problem: remote prescribing at scale, sometimes with minimal clinical assessment, and an e‑prescription system that can be exploited if governance is weak. At the same time, Polish authorities operate within EU food law, where CBD extracts for ingestion generally fall under Novel Food rules unless a valid authorization applies.
In practice, 2025 is a year where:
Industry coverage and legal commentary indicate that Poland moved to limit the ability of specialist clinics to issue prescriptions via teleconsultation without an in‑person examination—especially for controlled medicines. For example, CMS reported that the Ministry of Health discussed changes where only primary care physicians would be able to issue certain prescriptions during an online consultation, reflecting a tightening stance for controlled products.
Multiple industry sources cite a notable drop from the peak in October 2024 following the restriction of online prescribing.
While these are not official government statistical releases, they are consistent with the enforcement narrative: remote prescribing is being re‑anchored to clinical accountability and traceable medical justification.
A compliant model is not simply “video call + e‑prescription.” Clinics should treat remote care as a documentation-heavy medical service with clear triggers for in‑person review.
Key expectations to operationalize:
If your organization operates clinics (or partners with them), your compliance posture should be able to answer: “Why was this prescription appropriate for this patient, on this date, via this modality?”
A conservative pathway many operators are adopting:
Why it matters: if audited, the first in‑person exam provides a strong anchor for medical necessity.
If telemedicine initiation is still used in limited cases, the compliance burden goes up:
Brands should avoid building demand forecasts around “instant online prescriptions.” That channel is now structurally less reliable.
Poland’s model routes products through pharmacies, and controlled‑substance expectations cascade down to dispensing and recordkeeping.
Poland has continued modernizing its e‑prescription environment, and reporting indicates that prescriptions for narcotic/psychotropic products are issued electronically under tightened rules.
Even if you don’t operate the pharmacy, your supply chain will be judged by how “clean” it is:
Poland’s import and distribution of controlled substances sits within a licensing framework overseen by the Chief Pharmaceutical Inspectorate (GIF / Chief Pharmaceutical Inspectorate).
GIF’s official information for entrepreneurs and the controlled substances area highlights its role in issuing approvals for import or intra‑Community acquisition of narcotic drugs and psychotropic substances.
What importers should have organized (and retrievable fast):
Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) is the authority maintaining the Register of Medicinal Products admitted to trade.
The strategic takeaway: do not blur categories. A product should be clearly positioned and documented as a medicinal product, a medical device, a cosmetic, or a food supplement/food—and your labels, claims, and online listings must match that classification.
Under Regulation (EU) 2015/2283, a Novel Food requires pre‑market authorization if it was not consumed to a significant degree in the EU before 15 May 1997. EU institutions have long treated extracts containing cannabinoids (including CBD) as Novel Food absent a demonstrated history of consumption.
This is why “CBD oil as a food supplement” remains a high‑risk category in most EU countries, including Poland.
The RASFF Window (EU Rapid Alert System for Food and Feed) provides concrete examples of enforcement focus. In 2025, notifications explicitly reference unauthorized Novel Food CBD offered for sale online from Poland, with measures including sales bans.
For brands, this matters even if you are not based in Poland: cross‑border e‑commerce makes your Polish listing visible to other Member States, and enforcement can be triggered externally.
One reason the Novel Food pathway remains difficult is that EFSA has repeatedly highlighted data gaps around CBD safety. EFSA’s updated communication sets a provisional safe intake level while underscoring ongoing uncertainties.
Even if your dossier strategy is strong, your commercial plan must account for:
A Novel Food application is not a “formality.” It is a technical file intended to support EU‑wide authorization.
Common dossier elements to plan for:
Where brands commonly fail in Poland (and get delisted):
Poland’s Chief Sanitary Inspectorate (GIS) supervises food supplements. Market entry often involves notification rather than a formal pre‑approval, but that does not protect products that violate Novel Food or claims rules.
In other words: you can notify a supplement and still be investigated, challenged, or removed.
A practical overview of the notification concept (non‑official but consistent with practice) is widely described by Polish regulatory service providers, emphasizing that notification can trigger verification and withdrawals.
The commercial takeaway: treat GIS notification as a starting point for scrutiny, not a compliance shield.
In 2025, many brands underestimate the most immediate enforcement consequence: retailer delisting and payment/fulfillment disruption.
Triggers for delisting in Poland commonly include:
Once delisted, reinstatement typically requires more than “updated copy.” Expect requests for:
In Poland, the fastest way to reduce enforcement exposure is to stop straddling categories.
Actions:
Your website, product page, customer service scripts, influencer briefs, and FAQs should be reviewed to remove:
Treat claims compliance as part of cannabis compliance in the broad sense: enforcement often begins with marketing.
For each product, maintain a shareable folder containing:
This reduces downtime when platforms, distributors, or inspectors ask questions.
The telemedicine shift and delisting events can create sudden drops in access.
Brands that handle this well:
Plan for at least three operational scenarios:
If you operate in Poland—or sell into Poland via EU e‑commerce—2025’s reset is a reminder that compliance is your distribution strategy. Use https://cannabisregulations.ai/ to track regulatory updates, map compliant prescription and dispensing workflows, and build documentation checklists that hold up under scrutiny.
Informational only; consult qualified counsel for legal advice.
